Overexpression of YAP1 also contributed to poor outcomes and drug resistance in non-SCLC (NSCLC), liver cancer, stomach cancer, breast cancer, and colorectal carcinoma, in addition to SCLC [99–103]. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.